CircRNA hsa_circ_0005909 Promotes Cell Proliferation of Osteosarcoma Cells by Targeting miR-338-3p/HMGA1 Axis

References

• Kumar R, Kumar M, Malhotra K, Patel S. Primary osteosarcoma in the elderly revisited: current concepts in diagnosis and treatment. Curr Oncol Rep. 2018;20(2):13. doi:10.1007/s11912-018-0658-129492676
   PubMed Web of Science ®Google Scholar
• Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016;28(1):26–33. doi:10.1097/MOP.000000000000029826626558
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50. doi:10.1080/14737140.2018.141393929210294
   PubMed Web of Science ®Google Scholar
• Mir SM, Yousefi B, Marjani A, Rahimi M, Qujeq D. The sensitization of melatonin in osteosarcoma cells by suppression of anti-apoptotic proteins. Pharm Sci. 2020;26(2):159–164. doi:10.34172/PS.2020.3
   Web of Science ®Google Scholar
• Soghli N, Qujeq D, Yousefi T, Soghli N. The regulatory functions of circular RNAs in osteosarcoma. Genomics. 2020;112(4):2845–2856. doi:10.1016/j.ygeno.2020.03.02432243895
   PubMed Web of Science ®Google Scholar
• Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev. 2018;2018:7582730. doi:10.1155/2018/758273029743983
   PubMed Web of Science ®Google Scholar
• Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):Cd000951.
   PubMedGoogle Scholar
• Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2008;6(1):1–18. doi:10.1111/j.1476-5829.2007.00142.x19178659
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Synoradzki K, Firlej W, et al. Molecular biology of osteosarcoma. Cancers (Basel). 2020;12(8):2130. doi:10.3390/cancers12082130
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182–192. doi:10.1016/j.cca.2014.12.04125704303
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–157. doi:10.1261/rna.035667.11223249747
   PubMed Web of Science ®Google Scholar
• Cocquerelle C, Mascrez B, Hétuin D, Bailleul B. Mis-splicing yields circular RNA molecules. FASEB J. 1993;7(1):155–160. doi:10.1096/fasebj.7.1.76785597678559
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–388. doi:10.1038/nature1199323446346
   PubMed Web of Science ®Google Scholar
• Rajman M, Schratt G. MicroRNAs in neural development: from master regulators to fine-tuners. Development. 2017;144(13):2310–2322. doi:10.1242/dev.14433728676566
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun X, Icli B, Feinberg MW. Emerging roles for MicroRNAs in diabetic microvascular disease: novel targets for therapy. Endocr Rev. 2017;38(2):145–168.28323921
   PubMed Web of Science ®Google Scholar
• Li C, Zhang L, Meng G, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145(12):2875–2889. doi:10.1007/s00432-019-03045-431630262
   PubMed Web of Science ®Google Scholar
• Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):019–0089.
   PubMed Web of Science ®Google Scholar
• Skrzypek K, Majka M. Interplay among SNAIL transcription factor, MicroRNAs, long non-coding RNAs, and circular RNAs in the regulation of tumor growth and metastasis. Cancers. 2020;12(1):209. doi:10.3390/cancers12010209
   PubMed Web of Science ®Google Scholar
• Li S, Pei Y, Wang W, Liu F, Zheng K, Zhang X. Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2. Cell Cycle. 2019;18(11):1281–1291. doi:10.1080/15384101.2019.161812731116090
   PubMed Web of Science ®Google Scholar
• Jin Y, Li L, Zhu T, Liu G. Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma. Pathol Res Pract. 2019;215(12):152688. doi:10.1016/j.prp.2019.15268831727503
   PubMed Web of Science ®Google Scholar
• Xiao-Long M, Kun-Peng Z, Chun-Lin Z. Circular RNA circ_HIPK3 is down-regulated and suppresses cell proliferation, migration and invasion in osteosarcoma. J Cancer. 2018;9(10):1856–1862. doi:10.7150/jca.2461929805712
   PubMed Web of Science ®Google Scholar
• Ding S, Zhang G, Gao Y, Chen S, Cao C. Circular RNA hsa_circ_0005909 modulates osteosarcoma progression via the miR-936/HMGB1 axis. Cancer Cell Int. 2020;20:305. doi:10.1186/s12935-020-01399-132684842
   PubMed Web of Science ®Google Scholar
• Xu X-W, Zheng B-A, Hu Z-M, et al. Circular RNA hsa_circ_000984 promotes colon cancer growth and metastasis by sponging miR-106b. Oncotarget. 2017;8(53):91674–91683. doi:10.18632/oncotarget.2174829207676
   PubMedGoogle Scholar
• Zhang Y, Li J, Wang Y, Jing J, Li J. The roles of circular RNAs in osteosarcoma. Med Sci Monit. 2019;25:6378–6382. doi:10.12659/MSM.91555931446435
   PubMed Web of Science ®Google Scholar
• Chen G, Wang Q, Yang Q, et al. Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma. PLoS One. 2018;13(8):e0202896. doi:10.1371/journal.pone.020289630153287
   PubMed Web of Science ®Google Scholar
• Seok H, Lee H, Jang ES, Chi SW. Evaluation and control of miRNA-like off-target repression for RNA interference. Cell Mol Life Sci. 2018;75(5):797–814. doi:10.1007/s00018-017-2656-028905147
   PubMed Web of Science ®Google Scholar
• Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4(9):e252. doi:10.1038/mtna.2015.2326372022
   PubMedGoogle Scholar
• Sumter TF, Xian L, Huso T, et al. The high mobility group A1 (HMGA1) transcriptome in cancer and development. Curr Mol Med. 2016;16(4):353–393. doi:10.2174/156652401666616031615214726980699
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119. doi:10.1517/14728222.2011.64580522239440
   PubMed Web of Science ®Google Scholar
• Treff NR, Pouchnik D, Dement GA, Britt RL, Reeves R. High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene. 2004;23(3):777–785. doi:10.1038/sj.onc.120716714737112
   PubMed Web of Science ®Google Scholar
• Liau -S-S, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 2006;66(24):11613. doi:10.1158/0008-5472.CAN-06-146017178855
   PubMed Web of Science ®Google Scholar